Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
01 Dec 2022
01 Dec 2022
Historique:
received:
12
09
2021
accepted:
10
11
2022
entrez:
1
12
2022
pubmed:
2
12
2022
medline:
2
12
2022
Statut:
epublish
Résumé
HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in patients with high-risk early-stage breast cancer. I-SPY2 is a multicenter, phase II adaptively randomized neoadjuvant (NAC) clinical trial enrolling patients with stage II-III breast cancer with tumors 2.5 cm or larger on the basis of hormone receptors (HR), HER2 and Mammaprint status. Multiple novel investigational agents plus standard chemotherapy are evaluated in parallel for the primary endpoint of pathologic complete response (pCR). Patients with HER2-negative breast cancer were eligible for randomization to ganetespib from October 2014 to October 2015. Of 233 women included in the final analysis, 140 were randomized to the standard NAC control; 93 were randomized to receive 150 mg/m
Identifiants
pubmed: 36456573
doi: 10.1038/s41523-022-00493-z
pii: 10.1038/s41523-022-00493-z
pmc: PMC9715670
doi:
Banques de données
ClinicalTrials.gov
['NCT01042379']
Types de publication
Journal Article
Langues
eng
Pagination
128Subventions
Organisme : NCI NIH HHS
ID : R01 CA132870
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA225427
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Clin Cancer Res. 2009 Nov 15;15(22):7003-11
pubmed: 19887485
Clin Pharmacol Ther. 2009 Jul;86(1):97-100
pubmed: 19440188
NPJ Breast Cancer. 2017 Aug 25;3:31
pubmed: 28948212
Cell Death Dis. 2014 Sep 11;5:e1411
pubmed: 25210794
Invest New Drugs. 2014 Feb;32(1):14-24
pubmed: 23686707
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
Breast Cancer Res Treat. 2009 Jul;116(1):69-77
pubmed: 18592372
Org Biomol Chem. 2015 Feb 21;13(7):2108-16
pubmed: 25526223
Clin Cancer Res. 2012 Sep 15;18(18):4973-85
pubmed: 22806877
Nat Commun. 2017 Sep 6;8(1):451
pubmed: 28878208
Breast Cancer Res. 2017 Aug 2;19(1):89
pubmed: 28764748
PLoS One. 2011 Apr 14;6(4):e18552
pubmed: 21533169
Clin Cancer Res. 2012 Jan 1;18(1):64-76
pubmed: 22215907
Blood. 2010 Nov 25;116(22):4591-9
pubmed: 20651072
Adv Pharmacol. 2012;65:471-517
pubmed: 22959035
Clin Breast Cancer. 2016 Aug;16(4):276-83
pubmed: 26726007
Clin Breast Cancer. 2014 Jun;14(3):154-60
pubmed: 24512858
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
PLoS One. 2014 Feb 07;9(2):e88309
pubmed: 24516633
Nature. 2012 Oct 18;490(7420):351-2
pubmed: 23075983
N Engl J Med. 2016 Jul 7;375(1):23-34
pubmed: 27406347
Ann Oncol. 2015 Aug;26(8):1741-8
pubmed: 25997818
J Clin Oncol. 2020 Feb 20;38(6):613-622
pubmed: 31829907
Cell. 2007 Sep 21;130(6):1005-18
pubmed: 17889646
Adv Cancer Res. 2016;129:51-88
pubmed: 26916001
Breast Cancer Res. 2012 Apr 17;14(2):R62
pubmed: 22510516
J Clin Oncol. 2007 Oct 1;25(28):4414-22
pubmed: 17785706
Anticancer Drugs. 2004 Aug;15(7):651-62
pubmed: 15269596
Invest New Drugs. 2017 Jun;35(3):251-259
pubmed: 28111726
N Engl J Med. 2016 Jul 7;375(1):11-22
pubmed: 27406346
J Natl Compr Canc Netw. 2017 Apr;15(4):433-451
pubmed: 28404755
Nat Rev Mol Cell Biol. 2010 Jul;11(7):515-28
pubmed: 20531426
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Radiology. 2016 Apr;279(1):44-55
pubmed: 26624971
Exp Hematol. 2008 Oct;36(10):1266-77
pubmed: 18657349
Int J Cancer. 2009 Dec 15;125(12):2792-801
pubmed: 19544563
Cell Death Dis. 2021 Jan 26;12(1):126
pubmed: 33500390
Mol Cancer Res. 2014 Jul;12(7):1042-54
pubmed: 24784839